Incyte Corp
INCY- Exchange
- Nasdaq
- Industry
- Services-Commercial Physical & Biological Research
- SEC CIK
- 0000879169
In the last 90 days, Incyte Corp insiders filed 0 open-market purchases and 10 sales; 860 institutions reported holding it in 13F filings for Q2 2026, worth $23.0B in total; no superinvestor holds it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsLast 90 days, $18.2M in total
- 10
- 13F holdersQ2 2026, +53 vs. previous quarter
- 860
- 13F valueReported value at the end of Q2 2026
- $23.0B
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding INCY, Q2 2026
No superinvestor reported holding INCY at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by Incyte Corp insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 17, 2026 (view filing)4:04 PM ET | Sep 15 | 2 days | Cagnoni Pablo JPresident, Global Head of R&D | SSale | −23.2K | $120.49 | −$2.80M | −11.2%183.2K after | 2 lots10b5-1 |
| Aug 20, 2026 (view filing)5:15 PM ET | Aug 19 | 1 day | Cagnoni Pablo JPresident, Global Head of R&D | SSale | −10.8K | $125.56 | −$1.36M | −5.6%183.2K after | 10b5-1 |
| Aug 14, 2026 (view filing)4:01 PM ET | Aug 12 | 2 days | Cagnoni Pablo JPresident, Global Head of R&D | SSale | −10.8K | $120.04 | −$1.30M | −5.3%194.0K after | 10b5-1 |
| Aug 7, 2026 (view filing)4:02 PM ET | Aug 5 | 2 days | Cagnoni Pablo JPresident, Global Head of R&D | SSale | −10.6K | $122.69 | −$1.31M | −4.9%204.8K after | 10b5-1 |
| Aug 7, 2026 (view filing)4:01 PM ET | Aug 5 | 2 days | Mayes Patrick AEVP & Chief Scientific Officer | SSale | −2.21K | $123.99 | −$273.6K | −3.5%61.4K after | 10b5-1 |
| Aug 4, 2026 (view filing)4:04 PM ET | Jul 31 | 4 days | Cagnoni Pablo JPresident, Global Head of R&D | SSale | −15.9K | $119.70 | −$1.90M | −6.9%215.4K after | 10b5-1 |
| Aug 4, 2026 (view filing)4:04 PM ET | Jul 31-Aug 3 | 4 days | Mayes Patrick AEVP & Chief Scientific Officer | SSale | −48.0K | $119.58 | −$5.73M | −43.8%61.4K after | 12 lots10b5-1 |
| Jul 20, 2026 (view filing)4:10 PM ET | Jul 16 | 4 days | Stein Steven HCMO & Head of Late-Stage Dev. | SSale | −1.88K | $114.73 | −$215.3K | −8.2%21.1K after | 10b5-1 |
| Jul 20, 2026 (view filing)4:09 PM ET | Jul 16 | 4 days | Issa Mohamed KhairieEVP, Head of U.S. Commercial | SSale | −1.09K | $115.01 | −$125.7K | −1.7%63.9K after | 10b5-1 |
| Jul 16, 2026 (view filing)4:07 PM ET | Jul 15 | 1 day | Stein Steven HCMO & Head of Late-Stage Dev. | SSale | −28.2K | $113.05 | −$3.19M | −52.0%26.1K after | 10b5-1 |
Top 10 13F holders, Q2 2026
The largest institutional positions in Incyte Corp at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Baker Bros. Advisors LP | 30,762,330 | $3.49B | 17.48% | +17,918+0.1% | Added |
| BlackRock, Inc. | 18,032,718 | $2.04B | 0.03% | −945,480−5.0% | Reduced |
| Dodge & Cox | 11,957,326 | $1.36B | 0.71% | −295,030−2.4% | Reduced |
| Vanguard Capital Management LLC | 11,024,289 | $1.25B | 0.03% | +94,223+0.9% | Added |
| State Street Corp | 9,722,336 | $1.10B | 0.03% | +80,952+0.8% | Added |
| Vanguard Portfolio Management LLC | 7,791,091 | $883.2M | 0.04% | +31,908+0.4% | Added |
| AQR Capital Management LLC | 5,320,901 | $603.2M | 0.21% | −487,029−8.4% | Reduced |
| Geode Capital Management, LLC | 4,750,735 | $536.5M | 0.03% | +47,551+1.0% | Added |
| LSV Asset Management | 4,123,759 | $467.5M | 0.85% | +203,703+5.2% | Added |
| Invesco Ltd. | 4,080,461 | $462.6M | 0.04% | +209,697+5.4% | Added |